Sjogren's Syndrome and Small Fiber Neuropathy: A Common and Underrecognized Connection

Sjogren's syndrome is one of the most common — and most commonly missed — causes of small fiber neuropathy (SFN) and autonomic neuropathy. Studies suggest that 10–20% of Sjogren's patients have clinically significant SFN, and a substantial proportion of patients diagnosed with "idiopathic" SFN are ultimately found to have Sjogren's syndrome as the underlying cause. Understanding this connection is critical for appropriate diagnosis and treatment.

How Sjogren's Damages Small Nerve Fibers

Sjogren's syndrome is a systemic autoimmune condition characterized by lymphocytic infiltration of exocrine glands (salivary and lacrimal glands), producing the hallmark dry eyes and dry mouth. However, Sjogren's is also a systemic vasculitis and neuropathy — the same immune attack that damages glands also damages small nerve fibers throughout the body.

The mechanisms of Sjogren's-related SFN include:

Dorsal root ganglionopathy. The dorsal root ganglia (DRG) — clusters of sensory nerve cell bodies adjacent to the spinal cord — are a primary target of Sjogren's immune attack. Lymphocytic infiltration of the DRG (ganglioneuritis) destroys sensory neurons, producing a non-length-dependent SFN pattern (affecting the trunk and proximal limbs as well as the distal extremities).

Vasculitic neuropathy. Sjogren's-related vasculitis damages the small blood vessels (vasa nervorum) that supply peripheral nerves, causing ischemic nerve damage. This produces a length-dependent pattern affecting the distal extremities first.

Autoantibody-mediated damage. Anti-SSA (Ro) and anti-SSB (La) antibodies — the hallmark autoantibodies of Sjogren's — may directly damage nerve fibers and autonomic ganglia. Anti-SSA antibodies have been shown to block potassium channels on small nerve fibers, causing hyperexcitability and pain.

The Autonomic Neuropathy of Sjogren's

Sjogren's frequently causes autonomic neuropathy in addition to sensory SFN. Autonomic manifestations include:

• POTS: Orthostatic tachycardia from autonomic nerve damage affecting vascular regulation
• Anhidrosis: Reduced or absent sweating from damage to sudomotor fibers
• Gastroparesis: Delayed gastric emptying from vagal autonomic neuropathy
• Sicca symptoms beyond glands: Dry skin, dry vagina, dry trachea — from autonomic nerve damage to secretory glands throughout the body

The combination of sensory SFN (pain, burning, allodynia) and autonomic neuropathy (POTS, gastroparesis, anhidrosis) in the same patient should prompt evaluation for Sjogren's syndrome.

Diagnosing Sjogren's-Related SFN

Sjogren's antibodies: Anti-SSA (Ro) and anti-SSB (La) antibodies are present in 60–70% of Sjogren's patients. However, 30–40% of Sjogren's patients are seronegative — they have the disease but test negative for these antibodies. Seronegative Sjogren's is diagnosed by lip biopsy (showing lymphocytic infiltration of minor salivary glands) and clinical criteria.

Minor salivary gland biopsy: The gold standard for Sjogren's diagnosis. A small biopsy of the inner lip shows the characteristic lymphocytic infiltration (focus score ≥1) that confirms the diagnosis even in seronegative patients.

Schirmer's test and salivary flow: Objective measures of tear and saliva production that support the diagnosis.

Skin punch biopsy: Confirms SFN and characterizes the pattern (length-dependent vs. non-length-dependent), which helps identify the mechanism.

Treatment

Treating the underlying Sjogren's:

• Hydroxychloroquine (Plaquenil): Reduces systemic inflammation and may slow neuropathy progression
• Immunosuppressants (azathioprine, mycophenolate): For more severe systemic involvement
• IVIG: For severe autonomic or sensory neuropathy; evidence is strongest for ganglioneuritis
• Rituximab: For refractory cases with severe neuropathy

Symptomatic treatment of SFN:

• Neuropathic pain medications (duloxetine, pregabalin, gabapentin)
• Topical treatments (lidocaine patches, capsaicin cream)
• Alpha-lipoic acid (antioxidant with evidence for neuropathic pain)

Treating autonomic manifestations:

• POTS: Standard POTS management (sodium, fluids, compression, medications)
• Gastroparesis: Prokinetics, dietary modification
• Anhidrosis: Temperature management, cooling strategies

ChatDys resources: Upload your anti-SSA/SSB antibody results and lip biopsy results to Biomarkers. Track your neuropathic pain and autonomic symptoms in the Health Tracker. Review our IVIG for SFN article for information on immunotherapy options.